eFlow® rapid
Clinical Data

Pharmacokinetics
Compliance
Tolerability
Inhalation of Tobramycin (TOBI®) via eFlow® rapid versus PARI LC PLUS®

Clinical data confirms: ¹)

- Reduced inhalation time by more than half

- Reduced systemic serum levels

- Higher mean tobramycin sputum levels
  Mean tobramycin sputum levels were 1.8 fold higher for TOBI® administered via the eFlow® rapid than the PARI LC PLUS®.

- Maintained a similar safety profile
  Adverse events all mild-moderate. No clinically significant bronchospasm occurred.

¹) D Hubert, S Leroy, S Dominique, J Kovarik: Pharmacokinetic comparison of inhaled tobramycin (TOBI®) via PARI eFlow® rapid or PARI LC PLUS® nebulizers in cystic fibrosis patients. European Cystic Fibrosis Society, 30th Cystic Fibrosis Conference, Belek, Antalya-Turkey, 13-16 June 2007
Actual surveys about patient compliance:

eFlow® rapid had a positive influence on adherence.²)


eFlow® rapid reduces treatment burden significantly without altering lung function.³)

³) Fischer R, Nährig S, Kerscher M, Huber RM: Inhalation with PARI eFlow® rapid reduces treatment burden significantly in adult CF patients without altering lung function.

2)+3) European Cystic Fibrosis Society, 30th Cystic Fibrosis Conference, Belek, Antalya-Turkey, 13-16 June 2007
Hypertonic Saline 6% via eFlow® rapid

Clinical data confirms:
- Good tolerability
- Improved Compliance

40 adult CF patients inhaled two or four times daily 4ml of 6% hypertonic saline with the eFlow® rapid. Time for delivery was 3.9 ± 0.9 minutes, FEV₁ improved by 5% after two weeks with twice daily HS.

Outcomes of the bid treatment were comparable to those with the qid regimen, but tolerability was a lot better with HS administered only twice daily (refer to table). 90% of the subjects said that they would use this therapy on a long term basis.


NEW!

MucoClear® 6%

Inhalationslösung zur Sekretmobilisation in den unteren Atemwegen

20 x 4 ml NaCl (6%) – steril

Ohne Konserverungsmitel
Für Kinder unverzüglich aufzunehmen!

Medical Device Class I, sterile
More information: www.mucoclear.info

Therapy recommendation:
- Inhalation of 4 ml of 6% hypertonic saline twice daily
- Inhalation time for 4 ml: approx 4 min

More Information
PARI Pharma GmbH
Moostraße 3 • D- 82319 Starnberg
PARI Service Center: 08151/279-279
E-mail: info@pari.de
www.pari.de
www.eFlowrapid.info

PARI Pharma
Advancing Aerosol Therapies